These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34185525)

  • 21. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
    Dow GS; Chen Y; Andrews KT; Caridha D; Gerena L; Gettayacamin M; Johnson J; Li Q; Melendez V; Obaldia N; Tran TN; Kozikowski AP
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3467-77. PubMed ID: 18644969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and Synthesis of Novel Anti-Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit.
    Alves Avelar LA; Held J; Engel JA; Sureechatchaiyan P; Hansen FK; Hamacher A; Kassack MU; Mordmüller B; Andrews KT; Kurz T
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28317157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
    Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.
    Vallone A; D'Alessandro S; Brogi S; Brindisi M; Chemi G; Alfano G; Lamponi S; Lee SG; Jez JM; Koolen KJM; Dechering KJ; Saponara S; Fusi F; Gorelli B; Taramelli D; Parapini S; Caldelari R; Campiani G; Gemma S; Butini S
    Eur J Med Chem; 2018 Apr; 150():698-718. PubMed ID: 29571157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.
    Stopper D; de Carvalho LP; de Souza ML; Kponomaizoun CE; Winzeler EA; Held J; Hansen FK
    Eur J Med Chem; 2024 Nov; 277():116782. PubMed ID: 39208744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of alkoxyamide-based histone deacetylase inhibitors against Plasmodium falciparum malaria parasites.
    Dawood WA; Fisher GM; Kinnen FJM; Anzenhofer C; Skinner-Adams T; Alves Avelar L; Asfaha Y; Kurz T; Andrews KT
    Exp Parasitol; 2024 Mar; 258():108716. PubMed ID: 38340779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
    Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
    Nguyen W; Dans MG; Ngo A; Gancheva MR; Romeo O; Duffy S; de Koning-Ward TF; Lowes KN; Sabroux HJ; Avery VM; Wilson DW; Gilson PR; Sleebs BE
    Eur J Med Chem; 2021 Mar; 214():113253. PubMed ID: 33610028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of thymol-based pyrazolines: An effort to perceive novel potent-antimalarials.
    Raghuvanshi DS; Verma N; Singh SV; Khare S; Pal A; Negi AS
    Bioorg Chem; 2019 Jul; 88():102933. PubMed ID: 31048119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans.
    Malmquist NA; Sundriyal S; Caron J; Chen P; Witkowski B; Menard D; Suwanarusk R; Renia L; Nosten F; Jiménez-Díaz MB; Angulo-Barturen I; Santos Martínez M; Ferrer S; Sanz LM; Gamo FJ; Wittlin S; Duffy S; Avery VM; Ruecker A; Delves MJ; Sinden RE; Fuchter MJ; Scherf A
    Antimicrob Agents Chemother; 2015 Feb; 59(2):950-9. PubMed ID: 25421480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QSAR Classification Models for Prediction of Hydroxamate Histone Deacetylase Inhibitor Activity against Malaria Parasites.
    Hesping E; Chua MJ; Pflieger M; Qian Y; Dong L; Bachu P; Liu L; Kurz T; Fisher GM; Skinner-Adams TS; Reid RC; Fairlie DP; Andrews KT; Gorse AJP
    ACS Infect Dis; 2022 Jan; 8(1):106-117. PubMed ID: 34985259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
    Engel JA; Jones AJ; Avery VM; Sumanadasa SD; Ng SS; Fairlie DP; Skinner-Adams T; Andrews KT
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):117-26. PubMed ID: 26199860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
    Chen Y; Lopez-Sanchez M; Savoy DN; Billadeau DD; Dow GS; Kozikowski AP
    J Med Chem; 2008 Jun; 51(12):3437-48. PubMed ID: 18494463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimalarial and antiplasmodial activities of norneolignans. Syntheses and SAR.
    Skytte DM; Nielsen SF; Chen M; Zhai L; Olsen CE; Christensen SB
    J Med Chem; 2006 Jan; 49(1):436-40. PubMed ID: 16392829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.